Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced ...
Merck & Co's efforts to diversify its cancer pipeline beyond immunotherapy blockbuster Keytruda have taken a big step forward with a wide-ranging alliance with China's Kelun-Biotech that spans seven ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback